©The Author(s) 2025.
World J Gastroenterol. Nov 14, 2025; 31(42): 112577
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.112577
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.112577
Table 3 Changes in the gastrointestinal symptom scores of the study participants after intervention, mean ± SD
| Variables | Intervention group (n = 89) | Placebo-controlled group (n = 85) | Z | P value |
| GSRS score after 2 weeks of intervention - baseline GSRS score | ||||
| Reflux syndrome2-0 | -3.06 ± 1.50 | -2.58 ± 1.26 | 2.243 | 0.025a |
| Abdominal pain syndrome2-0 | -1.25 ± 2.11 | -1.46 ± 2.68 | 0.016 | 0.987 |
| Dyspepsia2-0 | -3.00 ± 3.66 | -2.58 ± 3.17 | 0.801 | 0.423 |
| Diarrhea2-0 | -1.70 ± 3.74 | -1.87 ± 2.83 | -0.831 | 0.406 |
| Constipation2-0 | -1.62 ± 3.08 | -1.62 ± 2.93 | -0.164 | 0.870 |
| GSRS total score2-0 | -8.63 ± 9.54 | -8.11 ± 8.30 | 0.495 | 0.620 |
| GSRS score after 4 weeks of intervention - baseline GSRS score | ||||
| Reflux syndrome4-0 | -3.09 ± 1.41 | -2.64 ± 1.34 | -1.933 | 0.053 |
| Abdominal pain syndrome4-0 | -1.93 ± 2.39 | -1.58 ± 2.68 | -0.754 | 0.451 |
| Dyspepsia4-0 | -3.89 ± 3.87 | -2.45 ± 3.59 | -1.813 | 0.070 |
| Diarrhea4-0 | -2.90 ± 3.21 | -1.60 ± 2.77 | -2.458 | 0.014a |
| Constipation4-0 | -1.74 ± 2.54 | -1.14 ± 2.87 | -1.525 | 0.127 |
| GSRS total score4-0 | -13.55 ± 9.26 | -9.40 ± 8.46 | -2.356 | 0.018a |
| GSRS score after 8 weeks of intervention - baseline GSRS score | ||||
| Reflux syndrome8-0 | -3.00 ± 1.41 | -2.62 ± 1.64 | -1.365 | 0.172 |
| Abdominal pain syndrome8-0 | -2.02 ± 2.32 | -1.60 ± 3.04 | -1.350 | 0.177 |
| Dyspepsia8-0 | -4.19 ± 3.75 | -2.59 ± 3.20 | -2.381 | 0.017a |
| Diarrhea8-0 | -2.98 ± 3.31 | -1.83 ± 2.62 | -1.846 | 0.065 |
| Constipation8-0 | -1.87 ± 3.02 | -1.36 ± 3.00 | -1.316 | 0.188 |
| GSRS total score8-0 | -14.06 ± 9.32 | -10.00 ± 8.56 | -2.279 | 0.023a |
- Citation: Liu WJ, Zhao YM, Xie QQ, Wu MC, Pan YF, Yan HK, Shan XX, Xu WT, Liu YL, Peng CX, Zhang XM, Lin Q. Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy for Helicobacter pylori infection. World J Gastroenterol 2025; 31(42): 112577
- URL: https://www.wjgnet.com/1007-9327/full/v31/i42/112577.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i42.112577